Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals, Inc. director and President of Research & Development David Young reported an open-market purchase of 1,786 shares of common stock at $2.57 per share on May 29, 2026. Following this transaction, he directly holds 17,131 common shares.
The filing also lists indirect holdings of common stock, including 742 shares held through CorLyst, LLC, 432 shares held through family entities, and 1,242 shares held through the Young-Plaisance Revocable Trust as of the same date.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of Common Stock. On May 29, 2026, he bought 2,292 shares at $2.57 per share, bringing his directly held position to 10,758 shares after the transaction.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,129 shares of Common Stock at $2.57 per share on May 29, 2026. Following this transaction, his direct holdings increased to 9,970 Common Stock shares.
The filing also lists indirect ownership positions of 800 Common Stock shares held through the Ng Cha Family Trust and 3,488 Common Stock shares held through an account labeled George Ng IRRA FOB George Ng, reflecting additional indirect exposure to Processa shares.
Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought additional company stock. On an open-market purchase, he acquired 1,582 shares of common stock at $2.57 per share. After this trade, he directly owns 9,176 shares. A separate holding entry shows 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,829 shares of Common Stock at $2.57 per share. After this trade, she directly owns 9,840 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng reported buying 1,843 shares of common stock in an open-market transaction at $2.97 per share. Following this purchase, he holds 7,841 shares directly.
The filing also shows indirect holdings of 800 shares through the Ng Cha Family Trust and 3,488 shares through an account labeled George Ng IRRA FOB George Ng. A footnote notes an immaterial correction to a prior Form 4, adjusting an April 30, 2026 purchase to $2.71 per share and reducing that earlier trade by 15 shares.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on May 15, 2026. After this trade, he directly holds 15,345 common shares.
The filing also reports indirect holdings of 742 shares through CorLyst, LLC, 432 shares through family entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date. A footnote states that share amounts were adjusted to correct immaterial errors in a prior Form 4, including a corrected April 30, 2026 purchase price of $2.71 per share instead of $2.69, which reduced that earlier purchase by 13 shares.
Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin reported an open-market purchase of 1,369 shares of common stock at $2.97 per share. Following this transaction, he directly owns 7,594 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.
A footnote states that share figures were adjusted to correct immaterial errors in a prior Form 4. The corrected price per share for a purchase on April 30, 2026 is $2.71 instead of $2.69, which reduced that earlier purchase by 11 shares.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,583 shares of common stock at $2.97 per share. After this trade, she directly holds 8,011 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.
The filing also corrects earlier data, noting that a purchase on April 30, 2026 was executed at $2.71 per share instead of $2.69, which reduces that earlier purchase by 13 shares. This adjustment is described as correcting immaterial errors in a prior Form 4.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of the company’s Common Stock. On May 15, he bought 1,984 shares at $2.97 per share, bringing his direct holdings to 8,466 shares.
The filing also notes that share totals were adjusted to correct immaterial errors in a prior Form 4. The corrected price for a purchase on April 30 is stated as $2.71 instead of $2.69, which reduced that earlier purchase by 16 shares.